期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Co-delivery of photosensitizer and diclofenac through sequentially responsive bilirubin nanocarriers for combating hypoxic tumors 被引量:3
1
作者 Yang Zhou Fan Tong +5 位作者 weilong gu Siqin He Xiaotong Yang Jiamei Li Yue-Dong Gao Huile Gao 《Acta Pharmaceutica Sinica B》 SCIE CAS CSCD 2022年第3期1416-1431,共16页
Considering that photodynamic therapy(PDT)-induced oxygen consumption and microvascular damage could exacerbate hypoxia to drive more glycolysis and angiogenesis, a novel approach to potentiate PDT and overcome the re... Considering that photodynamic therapy(PDT)-induced oxygen consumption and microvascular damage could exacerbate hypoxia to drive more glycolysis and angiogenesis, a novel approach to potentiate PDT and overcome the resistances of hypoxia is avidly needed. Herein, morpholine-modified PEGylated bilirubin was proposed to co-deliver chlorin e6, a photosensitizer, and diclofenac(Dc). In acidic milieu, the presence of morpholine could enable the nanocarriers to selectively accumulate in tumor cells, while PDT-generated reactive oxidative species(ROS) resulted in the collapse of bilirubin nanoparticles and rapid release of Dc. Combining with Dc showed a higher rate of apoptosis over PDT alone and simultaneously triggered a domino effect, including blocking the activity and expression of lactate dehydrogenase A(LDHA), interfering with lactate secretion, suppressing the activation of various angiogenic factors and thus obviating hypoxia-induced resistance-glycolysis and angiogenesis. In addition, inhibition of hypoxia-inducible factor-1a(HIF-1a) by Dc alleviated hypoxia-induced resistance. This study offered a sequentially responsive platform to achieve sufficient tumor enrichment, on-demand drug release and superior anti-tumor outcomes in vitro and in vivo. 展开更多
关键词 Bilirubin nanoparticles ROS-responsive drug release Charge reversal Photodynamic therapy Hypoxia DICLOFENAC LDHA inhibition HIF-1a inhibition
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部